Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03675412 · ClinicalTrials.gov registry record · NA
Caffeine Consumption in Glaucoma Patients and Healthy Subjects
A NA study of Glaucoma, Primary Open Angle, sponsored by Wills Eye.
- Recruiting
- Registry status
- NA
- Development phase
- 80
- Enrollment target
- 1
- Study location
NCT03675412: Recruiting NA study of Glaucoma, Primary Open Angle, sponsored by Wills Eye.
NCT03675412 is a NA study of Glaucoma, Primary Open Angle that is actively recruiting participants, run by Wills Eye. The registered enrollment target is 80 participants, above the 55-participant average among 5 other Glaucoma, Primary Open Angle trials with a reported enrollment target (45% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03675412, a NA study of Glaucoma, Primary Open Angle, is actively recruiting participants, sponsored by Wills Eye.
- RECRUITING
- Registry status
- NA
- Development phase
- 80 participants
- Enrollment target
- 1
- Study location
Study Summary
Caffeine is the most widely consumed drinking nutrient in the world. Caffeine effects various organs and the vascular system. It decreases ocular blood flow due to vasoconstriction.
Primary Outcome
Optical Coherence Tomography Angiography (OCTA) will be obtained using the Avanti AngioVue High Definition (HD) OCTA by Optovue. Images will include standard 4.5mm HD disc scan, 6mm HD retina scan, regular optic nerve head (ONH) structural scan, 3D-disc baseline scan and a regular ganglion cell complex analysis (GCCA) structural scan. This will measure blood flow changes in the back of the eye by imaging vessel density in percentage before then 1 and 2 hours after caffeine.
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT Caffeine tablet
Study Locations (1)
Pennsylvania
- Wills Eye Glaucoma Service - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2018-12-30 |
| Est. Completion | 2026-12-31 |
| Phase | NA |
What NCT03675412 shows while recruiting
NCT03675412 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 80 participants, a relatively small participant target, above the 55-participant average among 5 other Glaucoma, Primary Open Angle trials with a reported enrollment target (45% higher).
The record links to 1 condition, with Glaucoma, Primary Open Angle appearing as the primary indexed condition, and to 1 intervention - of which Caffeine tablet is the first listed.
NCT03675412 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT03675412 about?
NCT03675412 is a clinical study titled "Caffeine Consumption in Glaucoma Patients and Healthy Subjects". Caffeine is the most widely consumed drinking nutrient in the world. Caffeine effects various organs and the vascular system. It decreases ocular blood flow due to vasoconstriction.
What is the current status of trial NCT03675412?
This trial is currently recruiting. It is a NA study. The enrollment target is 80 participants. The study started on 2018-12-30. Estimated completion is 2026-12-31.
What conditions does trial NCT03675412 study?
This clinical trial studies the following conditions: Glaucoma, Primary Open Angle.
What interventions are being tested in trial NCT03675412?
The interventions under investigation include: Caffeine tablet (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT03675412?
This trial is sponsored by Wills Eye, which has 59 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03675412 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glaucoma, Primary Open Angle
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Adaptive Optics Retinal Imaging
RECRUITING · NA
-
Safety and Feasibility of the ELIOS System in POAG Patients
RECRUITING · NA
-
Safety and IOP-Lowering Effects of WB007
COMPLETED · Phase 1
-
Investigate, Following Cataract Surgery With IOL in Conjunction With Intracanalicular Dexamethasone Insert
COMPLETED · Phase 4
-
NT-501 CNTF Implant for Glaucoma: Safety, Neuroprotection and Neuroenhancement
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
- NCT01659203 · 80 participants · Phase 1
Proton or Photon RT for Retroperitoneal Sarcomas
- NCT01803451 · 80 participants · Early Phase 1
Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass
- NCT01964859 · 80 participants · Phase 2
Feasibility Study for Fibroblast Autologous Skin Grafts
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI